TST 008
Alternative Names: TST-008Latest Information Update: 28 Sep 2025
At a glance
- Originator Transcenta Holding
- Class Bispecific antibodies; Urologics
- Mechanism of Action Immunogenetic modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical IgA nephropathy; Lupus nephritis
- No development reported Kidney disorders; Systemic lupus erythematosus
Most Recent Events
- 28 Sep 2025 No recent reports of development identified for preclinical development in Systemic-lupus-erythematosus in China (Parenteral)
- 01 Aug 2024 Preclinical trials in IgA nephropathy in China (Parenteral), prior to August 2024 (Transcenta Holding pipeline, April 2024)
- 01 Aug 2024 Preclinical trials in Lupus nephritis in China (Parenteral), prior to August 2024 (Transcenta Holding pipeline, April 2024)